11400 WEST OLYMPIC BLVD., LOS ANGELES, CA
Announces Pricing of $150 Million Underwritten Offering of Common Stock
95% Complete Response Rate in Interim Update from Relapsed/Refractory AL Amyloidosis Clinical Trial
Annual Report to Security Holders
Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
Immix Biopharma Enters Amendment No. 1 to At The Market Offering Agreement
Underwriting Agreement for 19.1M Shares at $5.10 per Share
Immix Biopharma's Positive Phase 2 NXC-201 Results at ASH 2025
Other Events
Q1
Amended Annual Report
FY 2025
Q3
Q2
Amended Quarterly Report
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Free Writing Prospectus
Correspondence
Submission Upload